237 related articles for article (PubMed ID: 18288685)
1. Functional angiotensin II type 2 receptors inhibit growth factor signaling in LNCaP and PC3 prostate cancer cell lines.
Chow L; Rezmann L; Imamura K; Wang L; Catt K; Tikellis C; Louis WJ; Frauman AG; Louis SN
Prostate; 2008 May; 68(6):651-60. PubMed ID: 18288685
[TBL] [Abstract][Full Text] [Related]
2. Increased expression of heparin binding EGF (HB-EGF), amphiregulin, TGF alpha and epiregulin in androgen-independent prostate cancer cell lines.
Tørring N; Jørgensen PE; Sørensen BS; Nexø E
Anticancer Res; 2000; 20(1A):91-5. PubMed ID: 10769639
[TBL] [Abstract][Full Text] [Related]
3. Epidermal growth factor (EGF) receptor blockade inhibits the action of EGF, insulin-like growth factor I, and a protein kinase A activator on the mitogen-activated protein kinase pathway in prostate cancer cell lines.
Putz T; Culig Z; Eder IE; Nessler-Menardi C; Bartsch G; Grunicke H; Uberall F; Klocker H
Cancer Res; 1999 Jan; 59(1):227-33. PubMed ID: 9892211
[TBL] [Abstract][Full Text] [Related]
4. Growth hormone (GH) receptors in prostate cancer: gene expression in human tissues and cell lines and characterization, GH signaling and androgen receptor regulation in LNCaP cells.
Weiss-Messer E; Merom O; Adi A; Karry R; Bidosee M; Ber R; Kaploun A; Stein A; Barkey RJ
Mol Cell Endocrinol; 2004 May; 220(1-2):109-23. PubMed ID: 15196705
[TBL] [Abstract][Full Text] [Related]
5. Regulation of growth hormone receptors in human prostate cancer cell lines.
Bidosee M; Karry R; Weiss-Messer E; Barkey RJ
Mol Cell Endocrinol; 2009 Oct; 309(1-2):82-92. PubMed ID: 19540305
[TBL] [Abstract][Full Text] [Related]
6. Melatonin and prostate cancer cell proliferation: interplay with castration, epidermal growth factor, and androgen sensitivity.
Siu SW; Lau KW; Tam PC; Shiu SY
Prostate; 2002 Jul; 52(2):106-22. PubMed ID: 12111702
[TBL] [Abstract][Full Text] [Related]
7. Steroid receptor regulation of epidermal growth factor signaling through Src in breast and prostate cancer cells: steroid antagonist action.
Migliaccio A; Di Domenico M; Castoria G; Nanayakkara M; Lombardi M; de Falco A; Bilancio A; Varricchio L; Ciociola A; Auricchio F
Cancer Res; 2005 Nov; 65(22):10585-93. PubMed ID: 16288052
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin II up-regulates PAX2 oncogene expression and activity in prostate cancer via the angiotensin II type I receptor.
Bose SK; Gibson W; Giri S; Nath N; Donald CD
Prostate; 2009 Sep; 69(12):1334-42. PubMed ID: 19517575
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin receptors in hormone-independent prostate cancer cell line DU145: presence of two variants of angiotensin type 1 receptor.
Sidorkiewicz M; Rebas E; Szymajda M; Ławnicka H; Pawlikowski M; Lachowicz A
Med Sci Monit; 2009 Apr; 15(4):BR106-10. PubMed ID: 19333191
[TBL] [Abstract][Full Text] [Related]
10. Renin-angiotensin system is an important factor in hormone refractory prostate cancer.
Uemura H; Hasumi H; Ishiguro H; Teranishi J; Miyoshi Y; Kubota Y
Prostate; 2006 Jun; 66(8):822-30. PubMed ID: 16482568
[TBL] [Abstract][Full Text] [Related]
11. A cross-talk between the androgen receptor and the epidermal growth factor receptor leads to p38MAPK-dependent activation of mTOR and cyclinD1 expression in prostate and lung cancer cells.
Recchia AG; Musti AM; Lanzino M; Panno ML; Turano E; Zumpano R; Belfiore A; Andò S; Maggiolini M
Int J Biochem Cell Biol; 2009 Mar; 41(3):603-14. PubMed ID: 18692155
[TBL] [Abstract][Full Text] [Related]
12. Prostate cancer cells generated during intermittent androgen ablation acquire a growth advantage and exhibit changes in epidermal growth factor receptor expression.
Hobisch A; Fiechtl M; Sandahl-Sorensen B; Godoy-Tundidor S; Artner-Dworzak E; Ramoner R; Bartsch G; Culig Z
Prostate; 2004 Jun; 59(4):401-8. PubMed ID: 15065088
[TBL] [Abstract][Full Text] [Related]
13. Regulation of androgen receptor transactivity and mTOR-S6 kinase pathway by Rheb in prostate cancer cell proliferation.
Kobayashi T; Shimizu Y; Terada N; Yamasaki T; Nakamura E; Toda Y; Nishiyama H; Kamoto T; Ogawa O; Inoue T
Prostate; 2010 Jun; 70(8):866-74. PubMed ID: 20127734
[TBL] [Abstract][Full Text] [Related]
14. An AKT activity threshold regulates androgen-dependent and androgen-independent PSA expression in prostate cancer cell lines.
Paliouras M; Diamandis EP
Biol Chem; 2008 Jun; 389(6):773-80. PubMed ID: 18627304
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression.
Lee SO; Chun JY; Nadiminty N; Lou W; Gao AC
Prostate; 2007 May; 67(7):764-73. PubMed ID: 17373716
[TBL] [Abstract][Full Text] [Related]
16. Differential protein synthesis and expression levels in normal and neoplastic human prostate cells and their regulation by type I and II interferons.
Nagano K; Masters JR; Akpan A; Yang A; Corless S; Wood C; Hastie C; Zvelebil M; Cramer R; Naaby-Hansen S
Oncogene; 2004 Mar; 23(9):1693-703. PubMed ID: 14647428
[TBL] [Abstract][Full Text] [Related]
17. Transactivation of ErbB1 and ErbB2 receptors by angiotensin II in normal human prostate stromal cells.
Lin J; Freeman MR
Prostate; 2003 Jan; 54(1):1-7. PubMed ID: 12481249
[TBL] [Abstract][Full Text] [Related]
18. Intracellular signaling pathways regulating radioresistance of human prostate carcinoma cells.
Skvortsova I; Skvortsov S; Stasyk T; Raju U; Popper BA; Schiestl B; von Guggenberg E; Neher A; Bonn GK; Huber LA; Lukas P
Proteomics; 2008 Nov; 8(21):4521-33. PubMed ID: 18821526
[TBL] [Abstract][Full Text] [Related]
19. Genetic change in transforming growth factor beta (TGF-beta) receptor type I gene correlates with insensitivity to TGF-beta 1 in human prostate cancer cells.
Kim IY; Ahn HJ; Zelner DJ; Shaw JW; Sensibar JA; Kim JH; Kato M; Lee C
Cancer Res; 1996 Jan; 56(1):44-8. PubMed ID: 8548772
[TBL] [Abstract][Full Text] [Related]
20. Expression of serotonin receptors and role of serotonin in human prostate cancer tissue and cell lines.
Dizeyi N; Bjartell A; Nilsson E; Hansson J; Gadaleanu V; Cross N; Abrahamsson PA
Prostate; 2004 May; 59(3):328-36. PubMed ID: 15042609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
